Statistical Scientist (ID: 42412)
http://ats.staffxl.com/ATS/PortalViewRequirement.do?reqGK=42412
Responsibilities:
- Biostatistical lead for translational medicine, including design of
exploratory analyses of biomarkers and predictive/diagnostic assays for phase 1
clinical trials
- Work with clinical pharmacology to explore PK/PD relationships
- Work closely with the bioanalytical group in the analysis of novel assays and
with research to analyze biomarkers and diagnostic tests during preclinical
studies of toxicity and efficacy
Requirements:
- Proficiency in biostatistics, programming, and data management required.
- Minimum of 3 years industry experience.
- Preferred skills include PK/PD analysis, experience with genomic analyses,
development of diagnostics, and prior work in Experimental Medicine/Phase 1
programs, especially in oncology indications.
- Excellent interpersonal, presentation, and writing skills desired
About Seattle Genetics
Seattle Genetics is a clinical stage biotechnology company focused on the
development and commercialization of monoclonal antibody-based therapies for
the treatment of cancer and autoimmune disease. The company's lead product
candidate, brentuximab vedotin (SGN-35), is in a pivotal trial under a Special
Protocol Assessment (SPA) with the FDA. Brentuximab vedotin is empowered by
Seattle Genetics' proprietary ADC technology comprising highly potent synthetic
drugs and stable linkers for attaching the drugs to monoclonal antibodies. In
addition, Seattle Genetics has three other product candidates in ongoing
clinical trials: dacetuzumab (SGN-40), lintuzumab (SGN-33) and SGN-70.
Dacetuzumab is being developed under a worldwide collaboration with Genentech
(a wholly-owned member of the Roche Group). Seattle Genetics has collaborations
for its ADC technology with a number of leading biotechnology and
pharmaceutical companies. More information can be found at
www.seattlegenetics.com.